Contrive Datum Insights has published "Hyperbaric Oxygen Therapy Market Size, Share & Industry Analysis, By Chamber type (Monoplace Chambers, Multiplace Chambers, Portable / Soft-Sided (Mild HBOT) Chambers), Operating pressure range (Low Pressure, Standard Clinical Pressure (1.5-2.0 ATA), High Pressure (2.0-3.0 ATA), Deep/Multiplace Treatment Pressure (>3.0 ATA)), Clinical indication (Wound Healing, Decompression Sickness and Air/Gas Embolism, Carbon Monoxide and Smoke Inhalation Poisoning, Necrotizing Soft Tissue Infections and Refractory Osteomyelitis, Compromised Skin Grafts and Flaps, Delayed Radiation Injury, Thermal Burn Injury, Idiopathic Sudden Sensorineural Hearing Loss, Off-Label / Emerging Wellness Use), End user / site of care (Hospital-Based Hyperbaric Units, Specialty Wound Care Centers and Clinics, Ambulatory / Freestanding Hyperbaric Centers, Home Care Settings, Military, Government and Diving/Hazmat Facilities), Oxygen delivery/supply system (Oxygen Concentrator-Based Supply, Bulk Liquid Oxygen Supply, Compressed Oxygen Cylinder Supply, On-Site PSA Oxygen Generation Systems), Distribution channel (Direct Sales / Institutional Tenders, Third-Party Distributors and Dealers, Online / Direct-to-Consumer (Portable Chambers), Equipment Rental and Leasing Providers), Payer / reimbursement type (Government/Public Health Programs, Private Insurance and Managed Care, Workers' Compensation and Veterans' Programs, Out-of-Pocket / Self-Pay), Facility ownership model (Hospital-Owned/Integrated Units, Independent/Freestanding Wound Care Centers, Physician-Owned Clinics, Franchise/Chain Wellness Centers, Home/Individual Ownership), and Regional Forecast, 2026-2034". The study sizes the global hyperbaric oxygen therapy market at USD 5.6 billion in 2025 and projects growth from USD 6.05 billion in 2026 to USD 11.45 billion by 2034, a compound annual growth rate of 8.3% across the forecast period.
Hyperbaric oxygen therapy equipment covers pressurized chambers, oxygen delivery systems and the ancillary monitoring and safety equipment used to deliver oxygen to patients at pressure levels above normal atmospheric pressure for medical treatment. Chambers range from single-patient monoplace units and multi-patient multiplace rooms to portable, soft-sided units used for lower-pressure and wellness applications. Buyers include hospitals, specialty wound care centers, freestanding and ambulatory hyperbaric clinics, military and government diving and hazmat facilities, and increasingly individual or home buyers seeking maintenance and off-label wellness therapy.
Expanding reimbursement coverage for chronic wound care
Expanding reimbursement coverage for chronic wound care is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 8.3% a year, the chamber type lines exposed to it move fastest: Portable / Soft-Sided (Mild HBOT) Chambers compounds at 14.42%, taking its share of revenue from 12.68% to 21.05% and its value from USD 0.71 billion to USD 2.41 billion.
The study also runs a bull case: reimbursement coverage broadens faster than currently scheduled and off-label wellness adoption accelerates ahead of the base case. That path ends 2034 at USD 13.25 billion, above the USD 11.45 billion base case.
Against that, reimbursement coverage for wound care indications tightens or plateaus and capital spending on new chamber installations slows in hospital and government budgets. On that reading 2034 revenue stops at USD 10.35 billion. The weight of the problem sits in Monoplace Chambers: 58.39% of 2025 revenue growing at 6.9%, well under the market's 8.3%.
Monoplace Chambers Scale Against Portable / Soft-Sided (Mild HBOT) Chambers Momentum
Competition in the global hyperbaric oxygen therapy market runs along the chamber type axis, not the regional one. Monoplace Chambers holds 58.39% of 2025 revenue at USD 3.27 billion and remains the largest line through 2034 at 51.97%, making it the position hardest for a challenger to take. Portable / Soft-Sided (Mild HBOT) Chambers, growing at 14.42%, is where share actually changes hands. A supplier established in one is not thereby established in the other, so a field of this size persists in a market of USD 5.6 billion.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Chamber type | Monoplace Chambers | 58.39% · USD 3.27 billion | — |
| Operating pressure range | Standard Clinical Pressure (1.5-2.0 ATA) | 48.04% · USD 2.69 billion | Low Pressure 10.1% |
| Clinical indication | Wound Healing | 33.93% · USD 1.9 billion | Off-Label / Emerging Wellness Use 15.31% |
| End user / site of care | Hospital-Based Hyperbaric Units | 40% · USD 2.24 billion | Home Care Settings 16.75% |
| Oxygen delivery/supply system | Bulk Liquid Oxygen Supply | 38.04% · USD 2.13 billion | Oxygen Concentrator-Based Supply 12.6% |
| Distribution channel | Direct Sales / Institutional Tenders | 51.96% · USD 2.91 billion | Online / Direct-to-Consumer (Portable Chambers) 15.99% |
| Payer / reimbursement type | Government/Public Health Programs | 38.04% · USD 2.13 billion | Out-of-Pocket / Self-Pay 12.99% |
| Facility ownership model | Hospital-Owned/Integrated Units | 43.93% · USD 2.46 billion | Home/Individual Ownership 15.66% |
- Based on regional analysis, North America led the global hyperbaric oxygen therapy market in 2025 with 42.5% of global revenue at USD 2.38 billion, reaching USD 4.35 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 21.57% in 2025 to 28% in 2034, with revenue growing from USD 1.21 billion to USD 3.21 billion.
- Middle East and Africa remains the smallest region throughout, at 4% of 2025 revenue and 4% by 2034.
- The fastest chamber type line is Portable / Soft-Sided (Mild HBOT) Chambers, forecast to compound at 14.42% through the period.
- The United States is the largest single country market at USD 2.09 billion in 2025, 37.32% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across eight axes: by chamber type, and by operating pressure range, clinical indication, end user / site of care, oxygen delivery/supply system, distribution channel, payer / reimbursement type and facility ownership model. The headline total carries bear, base and bull cases at USD 10.35 billion and USD 13.25 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.